Table 4 Therapy with insulin and other antihyperglycemic medications at the time of visit (n = 241)

 Long-acting insulin analog

138 (57.3)

 New generation of long-acting basal insulin

81 (33.6)

 Intermediate-acting human insulin

3 (1.2)

 Rapid-acting insulin analog

200 (83.0)

 Short-acting human insulin

24 (10.0)

 Premixed analog insulin

10 (4.1)

 Premixed human insulin

2 (0.8)

 Metformin

20 (8.3)

 DPP4^a inhibitors

7 (2.9)

 SGLT2^b inhibitors

2 (0.8)

 GLP1^c receptor agonists

3 (1.2)

 Fixed dose combination of DPP4 inhibitor / Metformin

6 (2.5)